



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T: 91 80 2808 2808  
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/AJ/2023-24/90

September 18, 2023

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
<b>Scrip Code – 532523</b>	<b>Scrip Symbol – Biocon</b>

**Subject: Intimation under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), it is hereby informed that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Peter Bains as Biocon Group Chief Executive Officer, being a Senior Management Personnel w.e.f. September 18, 2023.

Mr. Peter Bains has accordingly vide his letter dated September 18, 2023, stepped down from his role as a Non-Executive Independent Director from the Board of Biocon Limited with immediate effect, to assume this executive role as Biocon Group Chief Executive Officer. Consequently, he has also ceased to be a Member of the Audit Committee, Risk Management Committee and Stakeholders Relationship Committee of the Company.

Further, the Company has received confirmation from Mr. Peter Bains that there are no other material reasons for his stepping down as an Independent Director other than those mentioned in his letter enclosed herewith as **Annexure - A**.



The requisite disclosure as required under Regulation 30 read with clause 7 and 7B of Part A of Schedule III of the SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as **Annexure - B**.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,  
For **Biocon Limited**

---

**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

September 18, 2023

To  
**The Board of Directors**  
**Biocon Limited**  
20<sup>th</sup> KM, Hosur Road,  
Electronics City,  
Bangalore – 560100

**Sub: Stepping down from the position of Independent Director of the Company**


I hereby tender my resignation from the position of Independent Director of the Company to take up a wider role as Biocon Group CEO, of the Biocon Group with immediate effect.

*I further confirm that there is no other material reason other than as mentioned above for my stepping down from the position of Independent Director of the Company.*

I take this opportunity to thank the Board of Directors for their continuous support and guidance during my tenure as an Independent Director.

Thanking you.

Yours faithfully,



---

Mr. Peter Bains  
DIN: 00430937

**ANNEXURE B**

**Details under Regulation 30 of the SEBI Listing Regulations read along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name	Mr. Peter Bains
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation as Independent Director  Appointment as Biocon Group CEO, Senior Management Personnel
3.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	September 18, 2023
4.	Brief profile (in case of appointment)	Enclosed as Annexure C
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
6.	Letter of Resignation along with detailed reason for resignation	Enclosed as Annexure A
7.	Name of listed entities in which the resigning director holds directorship, indicating the category of directorship and membership of board committees, if any	Mr. Peter Bains neither holds directorship in any Indian listed entity nor is a Member of any Board Committees
8.	The independent director shall, along with the detailed reasons, also provide confirmation that there are no other material reasons other than those provided.	Mr. Peter Bains has confirmed that there are no other material reasons for his resignation other than those mentioned in his resignation letter

## ANNEXURE C

### **Brief Profile of Mr. Peter Bains**



**Mr. Peter Bains**, 66 years, holds a bachelor's degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels with an extensive track record of leadership and success in building companies, businesses, teams and brands for over 30 years.

Peter brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO) and geography encompassing both developed and emerging markets.

Presently, Peter is the Non-Executive Director on the Board of Indivior PLC, a UK FTSE listed pharmaceuticals company, MiNA Therapeutics, a privately held UK biotech company and world leader in small activating RNA technology and Apterna, a privately held UK biotech engaged in aptamer discovery. Peter is also Non-Executive Chairman of ILC Therapeutics, a privately held Scottish biotechnology company.

Peter served as CEO and on the Board of Syngene International Limited (Syngene), subsidiary of the Company, for almost 6 years from 2010, and led the company to its successful public listing in 2015. He also served as CEO of Sosei Group, a Japanese listed biopharmaceutical company. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including Head of Global Marketing and Senior Vice President of commercial development for GSK's International region.